FDA Inspection 1327044 — Boehringer Ingelheim RCV GmbH & Co KG
The FDA completed an inspection of Boehringer Ingelheim RCV GmbH & Co KG on July 4, 2025 in Vienna. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- July 4, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Vienna (Austria)
Additional Details
Mutual Recognition Agreement (MRA)